Please assess the completion status of the following clinical trial:

Trial Title: Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age at least 18 years.~* Presence of symptoms of an ischemic stroke with a baseline National Institutes of Health Stroke Scale (NIHSS) scale of one up to 20 or due to an ipsilateral atherosclerotic \>50% stenosis of the extracranial internal carotid artery (ICA) as shown by ultrasonography.~* Latency between the onset of stroke symptoms and intended administration of the study drugs is not more than 24 hours.~* Latency between the intended administration of the study drugs and intended carotid endarterectomy is at least three days.~Exclusion Criteria:~* Documented peptic ulcer disease within the preceding 30 days.~* Septicemia or severe localized infection.~* Severe illness (active cancer or significant liver or renal disease) or disability.~* Alcohol or illicit drug abuse.~* Pregnancy.~* Need for chronic anticoagulant therapy (e.g. atrial fibrillation, deep venous thrombosis).~* Need for long-term daily nonsteroidal antiinflammatory drugs.~* Contraindications for platelet therapy such as severe bleeding disorder within the past three months prior to randomization (coagulopathy, platelet disorder including history of heparin-induced thrombopenia, hemorrhage) or significant retinopathy with hemorrhages and exudates.~* Hypersensitivity to abciximab, murine monoclonal antibodies or aspirin.~* Any preexisting intracranial neurological disease such as tumor or multiple sclerosis.~* Intracranial or intraspinal operation or trauma or lumbar puncture within the last 2 months.~* Cardiac lesions likely to cause cardioembolism.~* Suspicion of or established non-atherosclerotic carotid artery disease such as dissection or vasculitis (Takayasu disease, giant cell arteritis, significant collagen vascular disease, systemic necrotizing vasculitis, granulomatous angiitis of the nervous system).~* Participation in another acute stroke trial investigating drugs other than abciximab.~* Treatment for the present stroke with tissue plasminogen activator, urokinase or ancrod.~* ICH, aneurysm, vascular malformation or arteriovenous fistula or sinovenous thrombosis of the brain.~* Brain infarct involving the whole territory of the middle cerebral artery (MCA).~* Stupor or coma.~* Uncontrolled hypertension (systolic pressure \>200 mmHg and/or diastolic pressure \>110 mmHg).~* No informed consent.~* Contraindication to undergo magnetic resonance (MR) imaging (eg pacemaker).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).